DEA telemedicine prescribing in 2026: where the rules stand, and what to document

Updated October 19, 2026 · 5 min read

As of October 2026, DEA-registered practitioners can still prescribe Schedule II–V controlled substances through telemedicine without a prior in-person evaluation. DEA and HHS extended the pandemic-era flexibilities again, this time through December 31, 2026, to give DEA time to finish a permanent telemedicine rule. A special registration for telemedicine has been proposed but, as far as public updates show, not finalized.

Where the rules stand (October 2026)

• Telemedicine flexibilities: extended through December 31, 2026. Prescribing of Schedule II–V controlled substances via telemedicine without a prior in-person visit remains possible while they apply.
• Special registration for telemedicine: proposed on January 15, 2025, with three types of special registration. The proposal would add requirements such as PDMP checks, identity verification, data reporting and record retention. It has not been finalized according to the latest public updates we found.
• Buprenorphine for opioid use disorder: covered by a separate final rule that allows prescribing through a telemedicine encounter under specific conditions. Check the current conditions and effective date in the Federal Register.
• State law: many states have their own telehealth and controlled-substance rules. Where state rules are stricter, they still apply.
• After December 31, 2026: depends on whether DEA finalizes a permanent rule or extends the flexibilities again. Watch DEA and HHS announcements in the last quarter of the year.

What to plan for now

• Know which of your patients receive controlled substances only through telemedicine and have never had an in-person evaluation with you. They are the group affected if the flexibilities lapse without a replacement rule.
• Keep the date of any in-person evaluation easy to find in the chart.
• Check your state's telehealth prescribing rules, including any consent and PDMP requirements.
• Decide who in the practice will watch for the DEA announcement and update your workflow.

Documentation that holds up in any scenario

Whatever the final rule says, a clear note for each controlled-substance encounter makes review easier. Common elements:

• Visit modality: in person, audio-video or audio-only, and where you and the patient were located.
• Date of the last in-person evaluation, if there was one.
• Diagnosis, indication and the clinical reasoning for this medication.
• PDMP check, with date and time, where your state requires it.
• Risk assessment and alternatives considered.
• Counseling given: side effects, interactions, storage and disposal.
• Plan: dose, quantity, refills and follow-up.
• The patient's consent to telemedicine, where your state requires it.

This list is general documentation practice, not legal advice. Your state board, DEA guidance and your counsel decide what is required for your practice.

Where recordings and transcripts fit

Some practices dictate notes after the visit or record telehealth visits with the patient's consent. A transcript that an editor has checked against the audio makes it easier to confirm what was actually said — consent, counseling, the agreed plan — when you write or review the note. It does not replace the clinical note or the prescriber's judgement.